N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis

Wan-Xin Peng; Fei Liu; Jia-Hong Jiang; Hang Yuan; Ziqiang Zhang; Liu Yang; Yin-Yuan Mo

doi:10.1016/j.gendis.2022.02.014

您当前的位置：

首页 >

文章列表页 >

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis

Full-length article | 更新时间：2023-05-16

- N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
- N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
- Genes & Diseases 2023年10卷第2期
- 作者机构：
  
  1. Department of Colorectal Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  2. Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  3. Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health,Zhejiang,Hangzhou,China,310052
  4. Department of Surgical Oncology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health,Zhejiang,Hangzhou,China,310052
  5. Department of Medical Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College,Zhejiang,Hangzhou,China,310014
  6. Department of Pulmonary Medicine, Tongji Hospital, Tongji University,Shanghai,China,200065
  7. Cancer Center and Research Institute, University of Mississippi Medical Center,MS,Jackson,USA,39216
  8. Department of Pharmacology/Toxicology, University of Mississippi Medical Center,MS,Jackson,USA,39216
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.02.014
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-3-1，
扫描看全文
N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis[J]. Genes & Diseases, 2023,10(2).

Wan-Xin Peng, Fei Liu, Jia-Hong Jiang, et al. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis[J]. Genes & Diseases, 2023,10(2).
N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis[J]. Genes & Diseases, 2023,10(2). DOI： 10.1016/j.gendis.2022.02.014.

Wan-Xin Peng, Fei Liu, Jia-Hong Jiang, et al. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis[J]. Genes & Diseases, 2023,10(2). DOI： 10.1016/j.gendis.2022.02.014.

摘要

Abstract

umulating evidence indicates that RNA methylation at N

-methyladenosine (m6A) plays an important regulatory role in gene expression and aberrant mRNA m6A modification is often associated with a variety of cancers. However

little is known whether and how m6A-modification impacts long non-coding RNA (lncRNA) and lncRNA-mediated tumorigenesis

particularly in pancreatic ductal adenocarcinoma (PDAC). In the present study

we report that a previously uncharacterized lncRNA

LINC00901

promotes pancreatic cancer cell growth and invasion and moreover

LINC00901 is subject to m6A modification which regulates its expression. In this regard

YTHDF1 serves as a reader for the m6A modified LINC00901 and downregulates the LINC00901 level. Notably

two conserved m6A sites in LINC00901 are critical to the recognition of LINC00901 by YTHDF1. Finally

RNA sequencing (RNA-seq) and gene function analysis revealed that LINC00901 positively regulates MYC through upregulation of IGF2BP2

a known RNA binding protein that can enhance MYC mRNA stability. Together

our results suggest that there is a LINC00901-IGF2BP2-MYC axis through which LINC00901 promotes PDAC progression in an m6A dependent manner.

关键词

Keywords

IGF2BP2LINC00901MYCN6-methyladenosine modification (m6A)PDACYTHDF1

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (PVT1) in human diseases

PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis

M6A modification of circNSUN2 promotes colorectal liver metastasis